A Possible New Treatment for HTLV-1-associated Myelopathy

    loading  Checking for direct PDF access through Ovid

Abstract

SYNOPSIS: Mogamulizumab reduces central nervous system inflammation and improves spasticity in patients with HTLV-1-associated myelopathy.

SOURCE: Sato T, Coler-Reilly ALG, Yagishita N, et al. Mogamulizumab (anti-CCR4) in HTLV-1-associated myelopathy. N Engl J Med 2018;378:529-538.

Related Topics

    loading  Loading Related Articles